Fed Chair Jerome Powell answers CBS News 60 Minutes questions about the recent U.S. economic outlook.

Dan Rochefort

2019-03-29 12:28:00 Fri ET

Federal Reserve Chair Jerome Powell answers CBS News 60 Minutes questions about the recent U.S. economic outlook and interest rate cycle. Powell views the current U.S. economic outlook as a favorable one. The federal funds rate hits the neutral threshold where the U.S. economy operates near full employment with low inflation. Powell reiterates the *patient* approach to further raising the interest rate as the U.S. economy grows at a moderate pace.

Although about 7 million Americans fall behind their auto loan payments and retail sales decline at the highest pace in the post-crisis period, Powell remains positive about U.S. economic growth in 2019-2020. As the American real GDP growth rate increases above 3%, there are healthy upticks in both wage growth and consumer confidence.

In light of the recent Sino-U.S. trade and Brexit negotiations, Powell considers the biggest macro risk to be a likely economic output slowdown in China and Europe. Powell considers the U.S. financial system to be more resilient with high capital buffers that help absorb extreme losses in key times of severe financial stress. The Federal Reserve is independent in the generic sense that the monetary authority needs to execute monetary policy decisions in a strictly non-political way.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

AYA free finbuzz podcast channel on YouTube March 2019

Andy Yeh Alpha

2019-03-31 11:40:00 Sunday ET

AYA free finbuzz podcast channel on YouTube March 2019

AYA Analytica free finbuzz podcast channel on YouTube March 2019 In this podcast, we discuss several topical issues as of March 2019: (1) Sargent-Wallac

+See More

President Xi seeks Chinese congressional approval for abolishing his term limits of strongman rule with better trade deals and economic ties.

Jacob Miramar

2018-03-03 11:37:00 Saturday ET

President Xi seeks Chinese congressional approval for abolishing his term limits of strongman rule with better trade deals and economic ties.

President Xi seeks Chinese congressional approval and constitutional amendment for abolishing his term limits of strongman rule with more favorable trade de

+See More

We share Warren Buffett's famous quotes on fundamental stock investment.

Charlene Vos

2017-07-19 11:35:00 Wednesday ET

We share Warren Buffett's famous quotes on fundamental stock investment.

This brief article encapsulates the timeless wisdom of Warren Buffett's famous quotes on fundamental stock investment, fear and greed, patience, risk co

+See More

Federal Reserve raises the interest rate to the target range of 2.25% to 2.5% as of December 2018.

Charlene Vos

2018-12-22 14:38:00 Saturday ET

Federal Reserve raises the interest rate to the target range of 2.25% to 2.5% as of December 2018.

Federal Reserve raises the interest rate to the target range of 2.25% to 2.5% as of December 2018. Fed Chair Jerome Powell highlights the dovish interest ra

+See More

Most major economies grow with great synchronicity several years after the global financial crisis.

John Fourier

2018-01-19 11:32:00 Friday ET

Most major economies grow with great synchronicity several years after the global financial crisis.

Most major economies grow with great synchronicity several years after the global financial crisis. These economies experience high stock market valuation,

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More